written on 24.06.2014

Affymax, once a promising biotech, is dissolving


Affymax, which 18 months ago appeared poised for big things, is dissolving the company and will pay shareholders pennies for the shares that traded at $27 a share before patient deaths led it to pulled its Omontys anemia drug from the market.